Patents Examined by Susan Ungar
  • EphA2 monoclonal antibodies and methods of making and using same
    Patent number: 7101976
    Abstract: The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: September 5, 2006
    Assignees: Purdue Research Foundation, SmithKline Beecham Corporation
    Inventors: Katherine E Kilpatrick, Michael Scott Kinch, Kelly Carles-Kinch
  • Murine monoclonal anti-idiotype antibody 3H1 sequences for human carcinoembryonic antigen
    Patent number: 7090842
    Abstract: This invention provides compositions derived from the sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 3H1 and methods for using these compositions.
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: August 15, 2006
    Assignee: Board of Trustees of the University of Kentucky
    Inventors: Malaya Chatterjee, Heinz Kohler, Sunil K. Chatterjee, Kenneth A. Foon
  • Peptide for triggering an immune reaction against tumor cells
    Patent number: 7087712
    Abstract: The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: August 8, 2006
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Peter Brossart, Stefan Stevanovic, Wolfram Brugger, Lothar Kanz, Hans-Georg Rammensee
  • Apoptosis related polynucleotides, polypeptides, and antibodies
    Patent number: 7078186
    Abstract: The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: July 18, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Paul E. Young, Steven M. Ruben
  • Selective binding agents of telomerase
    Patent number: 7078491
    Abstract: The present invention relates to novel selective binding agents including polyclonal and monoclonal antibodies that recognize and bind to the catalytic subunit of human telomerase (hTERT). The invention also relates to the production, diagnostic use, and therapeutic use of the hTERT antibodies and fragments thereof.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: July 18, 2006
    Assignee: Amgen Inc.
    Inventor: Lea A. Harrington
  • Androgen regulated prostate specific nucleic acids
    Patent number: 7071303
    Abstract: The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: July 4, 2006
    Assignee: Institute For Systems Biology
    Inventor: Biaoyang Lin
  • Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
    Patent number: 7067630
    Abstract: The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment by utilizing the DNA and/or protein disclosed herein.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: June 27, 2006
    Assignee: The Board of Trustees of The University of Arkansas System
    Inventors: Timothy J. O'Brien, Lowell J. Underwood
  • Nucleotide and deduced amino acid sequences of tumor gene Int6
    Patent number: 7067635
    Abstract: The present invention discloses the isolation of the human and murine wild-type Int6 gene and the cDNAs sorresponding to these genes. The invention further describes the use of reagents derived from the nucleic acid and amino acid sequences of the Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines.
    Type: Grant
    Filed: February 19, 2004
    Date of Patent: June 27, 2006
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Antonio Marchetti, Fiamma Buttitta, Gilbert H. Smith, Robert Callahan
  • Breast cancer transcription factor gene and uses
    Patent number: 7053193
    Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides, Urb-ctf, are expressed in breast cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions especially related to breast cancer.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: May 30, 2006
    Assignee: Origene Technologies, Inc.
    Inventors: Zairen Sun, Wufang Fan, Karl F. Kovacs, Xuan Li, Gilbert Jay
  • Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
    Patent number: 7045596
    Abstract: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of ?SARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: May 16, 2006
    Assignee: Tanox, Inc.
    Inventors: Samuil Umansky, Hovsep Melkonyan
  • Survivin-binding proteins, encoding nucleic acids, and methods of use
    Patent number: 7041783
    Abstract: In accordance with the present invention, there are provided novel Survivin-binding-proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and in bioassays methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: May 9, 2006
    Assignee: The Burnham Institute
    Inventors: John C. Reed, Kazuya Okada
  • Method of inhibiting immune system destruction of transplanted viable cells
    Patent number: 7041634
    Abstract: This invention provides a method of inhibiting viable cells transplanted into a subject from being destroyed by the subject's immune system which comprises: a) containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; and b) treating the subject with a substance which inhibits an immune-system costimulation event in an amount effective to inhibit the subject's immune system from responding to said contained cells or tissue. In one embodiment, the substance which inhibits an immune-system costimulation event is CTLA4.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: May 9, 2006
    Assignees: Emory University, Bristol Myers-Squibb Company
    Inventors: Collin J. Weber, Mary K. Hagler, Peter S. Linsley, Judith A. Kapp, Susan A. Safley
  • Antibody purification
    Patent number: 7038017
    Abstract: A process for purifying an antibody is provided. In this process, a mixture containing the antibody and a contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) at low salt concentration. The antibody is eluted from the column in the fraction which does not bind thereto. This process can be preceded and followed by other purification steps.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: May 2, 2006
    Assignee: Genentech, Inc.
    Inventors: Ernst H. Rinderknecht, Gerardo A. Zapata
  • Genes regulating programmed cell death
    Patent number: 7033767
    Abstract: The present invention to amino acid sequences of proteins that are associated with apoptosis and the use of these proteins in the diagnosis, prevention and treatment of disorders associated with abnormal cell proliferation and apoptosis. The invention relates as well to nucleotide sequences encoding the peptides, recombinant vectors carrying the sequences, recombinant host cells including either the sequences or vectors, and recombinant peptides. The invention further includes methods for using the nucleotide sequences and recombinant peptides in diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: April 25, 2006
    Assignee: University of Maryland Biotechnology Institute
    Inventor: Eric H. Baehrecke
  • Methods for diagnosis and treatment of MDK1 signal transduction disorders
    Patent number: 7034112
    Abstract: The present invention relates to MDK1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for diseases or conditions characterized by an abnormality in a signal transduction disorder. The signal transduction pathway involves an interaction between a MDK1 receptor tyrosine kinase and a receptor for the kinase. The MDK1 receptor tyrosine kinase may be truncated and lack a kinase domain and may be selected from the group consisting of MDK1.T1, MDK1.T2, MDK1.?1 and MDK1.?2.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: April 25, 2006
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften, e.V.
    Inventors: Thomas Ciossek, Axel Ullrich, Birgit Millauer
  • E25A protein, methods for producing and use thereof
    Patent number: 7030232
    Abstract: The invention provides a human E25a protein which is upregulated in cancerous cells, including those of hormone refractory prostate cancer, colon cancer, breast cancer or other cancers of epithelial origin. The invention also provides nucleic acid molecules encoding E25a protein, nucleic acid probes which hybridize with nucleic acid molecules encoding E25a protein, and antibodies which bind E25a protein. E25a protein and its related molecules can be useful as diagnostic markers of cancer, including hormone refractory prostate cancer, and as specific therapeutic targets in this disease. The invention also provides methods for diagnosing cancer, including hormone refractory prostate cancer.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: April 18, 2006
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte, Charles L. Sawyers
  • Reg-like protein
    Patent number: 7026127
    Abstract: Methods of detecting the presence of a tumor or a cancerous condition includes detecting the expression of RELP proteins, related polypeptides and proteins, or nucleic acid molecules indicative of such expression are presented. These methods include antibody-based assays and molecular diagnostic assays such as PCR-based methods.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: April 11, 2006
    Inventor: Marja Heiskala
  • Human SDF-5 protein and compositions
    Patent number: 7026445
    Abstract: Purified human SDF-5 proteins and processes for producing them are disclosed. DNA molecules encoding the human SDF-5 proteins are also disclosed. The proteins may be used in regulating the binding of Wnt genes to their receptor. In preferred embodiments, the proteins may be used for inducing formation, growth, differentiation, proliferation and/or maintenance of chondrocytes and/or cartilage tissue, and for other tissue repair, such as pancreatic tissue repair.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: April 11, 2006
    Assignee: Genetics Institute, LLC
    Inventors: Edward R. LaVallie, Lisa A. Racie, Gary Hattersley
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
    Patent number: 7022819
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: April 4, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Expression of functional antibody fragments
    Patent number: 7018809
    Abstract: Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab? and F(ab?)2 antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.
    Type: Grant
    Filed: September 18, 1992
    Date of Patent: March 28, 2006
    Assignee: Genentech, Inc.
    Inventor: Paul J. Carter